Current status and future prospects for satraplatin, an oral platinum analogue

Clinical Cancer Research

Volumn 14, Issue 6, 2008, Pages 1633-1638

  Choy, Hak ^a,b   Park, Clinton ^a   Yao, Min ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; OXALIPLATIN; PACLITAXEL; PLACEBO; PLATINUM AMMINE CYCLOHEXYLAMINE DICHLORIDE; PLATINUM DERIVATIVE; PREDNISONE; SATRAPLATIN; SEROTONIN ANTAGONIST; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CROSS RESISTANCE; CYTOTOXICITY; DIARRHEA; DRUG ABSORPTION; DRUG APPROVAL; DRUG BINDING; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG STRUCTURE; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NAUSEA; NONHUMAN; OVERALL SURVIVAL; PAIN; PLASMACYTOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RADIATION DOSE; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; UTERINE CERVIX CANCER; VOMITING;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; LUNG NEOPLASMS; MALE; MODELS, BIOLOGICAL; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; PLATINUM COMPOUNDS; PROSTATIC NEOPLASMS;

EID: 41549164880     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-2176     Document Type: Review

References (64)

1. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons fromthe first decade. Clin Cancer Res 2008;14:1634-42.
2. Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN, Gandara DR. Aurora kinases as anticancer drug targets. Clin Cancer Res 2008;14:1624-33.
3. Lee JJ, Swain SM. The epothilones: translating from the laboratory to the clinic. Clin Cancer Res 2008;14:1643-9.
4. Bennouna J, Delord JP, Campone M, Pinel M. Vinflunine: a new microtubule inhibitor agent. Clin Cancer Res 2008;14:1610-7.
5. Teicher BA. Newer cytotoxic agents: attacking cancer broadly. Clin Cancer Res 2008;14:1650-7.
6. Kelland LR. An update on satraplatin: the first orally available platinum anticancer drug. Exp Opin Investig Drugs 2000;9:1373-82.
7. Ormerod MG, Orr RM, O'Neill CF, et al. The cytotoxic action of four ammine/amine platinum(IV) dicarboxylates: a flow cytometric study. British journal of cancer 1996;74:1935-43.
8. Mellish KJ, Barnard CF, Murrer BA, Kelland LR. DNA binding properties of novel cis and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines. International journal of cancer 1995;62:717 -23.
9. 2], a metabolite of an orally active platinum anticancer drug. J Am Chem Soc 1992;114:5646-54.
10. O'Neill CF, Koberle B, Masters JR, Kelland LR. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin. British journal of cancer 1999;81:1294-303.
11. Reardon JT, Vaisman A, Chaney SG, Sancar A. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis-aceto-ammine-dichloro- cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer research 1999;59:3968-71.
12. Fink D, Nebel S, Aebi S, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer research 1996;56:4881-6.
13. Vaisman A, Lim SE, Patrick SM, et al. Effect of DNA polymerases and high mobility group protein 1on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts. Biochemistry 1999;38:11026-39.
14. Fokkema E, Groen HJ, Helder MN, de Vries EG, Meijer C. JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin. Biochemical pharmacology 2002;63:1989-96.
15. Wosikowksi K, Caligiuri M, Lamphere L. Efficacy of satraplatin, an oral platinum analogue in prostate cancer: synergistic activity with docetaxel. In: ASCO Prostate Cancer Symposium, San Francisco, CA; 2006. Abstract no. 351.
16. Wosikowski K, Lamphere L, Unteregger G, et al. Preclinical antitumor activity of the oral platinum analog satraplatin. Cancer Chemother Pharmacol 2007;60:589-600.
17. Kelland LR, Abel G, McKeage MJ, et al. Preclinical antitumor evaluation of bis-acetato-amminedichloro-cyclohexylamine platinum(IV): an orally active platinumdrug. Cancer research 1993;53:2581-6.
18. O'Neill CF, Hunakova L, Kelland LR. Cellular pharmacology of cis and trans pairs of platinum-complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells. Chem Biol Inter 1999;123:11-29.
19. Mellish KJ, Kelland LR, Harrap KR. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin. Br J Cancer 1993;68:240-50.
20. Martelli L, Di Mario F, Ragazzi E, et al. Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells. Biochem Pharmacol 2006;72:693-700.
21. Twentyman PR, Wright KA, Mistry P, Kelland LR, Murrer BA. Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin. Cancer Res 1992;52:5674 -80.
22. Wosikowski K. Efficacy of satraplatin (JM-216) is maintained in taxane-resistant tumors. In: 1st Conference on Cancer Therapeutics - Molecular Targets, Pharmacology and Clinical Applications, International Chemotherapy Society; 2004; Florence; 2004.
23. Sova P, Mistr A, Kroutil A, Zak F, Pouckova P, Zadinova M. Comparative anti-tumor efficacy of two orally administered platinum(IV) drugs in nude mice bearing human tumor xenografts. Anticancer drugs 2006;17:201-6.
24. Lamphere L, Obermayr F, Caligiuri M, et al. Satraplatin, an oral platinum analog, is active and synergistic with paclitaxel and docetaxel in prostate carcinoma models. J Clin Oncol Meeting Abstracts 2006;24:14620.
25. Obermayr F. Synergistic in vitro anticancer activity with sequential schedules of JM-118, a metabolite of satraplatin, in combination with erlotinib, paclitaxel, or 5-FU. In: AACR-NCI-EORTC Conference; 2005. Poster no. A216.
26. Oncodesign Study No. 050044: Tolerance and antitumor activity study of satraplatin in combination with capecitabine in nude mice bearing subcutaneous human bresat tumors. 2006.
27. Peters GJ. Synergistic interaction between erlotinib and JM118, the active metabolite of satraplatin. Eur J Cancer 2006(4 supplements):poster no. 614.
28. Rose WC. Combination chemotherapy involving orally administered etoposide and JM-216 in murine tumor models. Cancer Chemother Pharmacol 1997;40:51-6.
29. Obermayr F. Synergistic in vitro anticancer activity of JM118, a metabolite of satraplatin, in combination with Herceptin. In: AACR Conference; 2006. Poster no.1350.
30. Amorino GP, Mohr PJ, Hercules SK, Pyo H, Choy H. Combined effects of the orally active cisplatin analog, JM216, and radiation in antitumor therapy. Cancer Chemother Pharmacol 2000;46:423-6.
31. Raynaud FI, Mistry P, Donaghue A, et al. Biotransformation of the platinum drug JM216 following oral administration to cancer patients. Cancer Chemother Pharmacol 1996;38:155-62.
32. Poon GK, Raynaud FI, Mistry P, et al. Metabolic studies of an orally active platinum anticancer drug by liquid chromatography-electrospray ionization mass spectrometry. J Chromatograph 1995;712:61-6.
33. McKeage MJ, Mistry P, Ward J, et al. A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration. Cancer Chemother Pharmacol 1995;36:451-8.
34. McKeage MJ, Raynaud F, Ward J, et al. Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J Clin Oncol 1997;15:2691-700.
35. Kurata T, Tamura T, Sasaki Y, et al. Pharmacokinetic and pharmacodynamic analysis of bis-acetato-amminedichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: a phase I study. Jpn J Clin Oncol 2000;30:377-84.
36. Sessa C, Minoia C, Ronchi A, et al. Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days. Ann Oncol 1998;9:1315-22.
37. Vouillamoz-Lorenz S, Buclin T, Lejeune F, Bauer J, Leyvraz S, Decosterd LA. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days. Anticancer Res 2003;23:2757-65.
38. Beale P, Raynaud F, Hanwell J, et al. Phase I study of oral JM216 given twice daily. Cancer Chemother Pharmacol 1998;42:142-8.
39. Fokkema E, deVries EG, Meijer S, Groen HJ. Lack of nephrotoxicity of new oral platinum drug JM216 in lung cancer patients. Cancer Chemother Pharmacol 2000;45:89-92.
40. DeMario MD, Ratain MJ, Vogelzang NJ, et al. A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro- cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days. Cancer Chemother Pharmacol 1999;43:385-8.
41. Jones S, Hainsworth J, Burris HA III, et al. Phase I study of JM-216 (an oral platinum analogue) in combination-with paclitaxel in patients with advanced malignancies. Invest New Drugs 2002;20:55-61.
42. Cmelak AJ, Choy H, Murphy BA. Phase I study of JM-216 with concurrent radiation in non-small cell lung cancer and squamous cell head and neck cancer [abst 1520]. Proc Am Soc Clin Oncol 1999;18:393a.
43. George CM, Haraf DJ, Mauer AM, et al. A phase I trial of the oral platinum analogue JM216 with concomitant radiotherapy in advanced malignancies of the chest. Invest New Drugs 2001;19:303-10.
44. Hoffman PC. Oral JM-216 plus concomitant radiotherapy (RT) for patients (PTS) with advancedmalignancies of the chest [abstract 1878]. Proc Am Soc Clin Oncol 1998;17:488a.
45. This was set as footnote.
46. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993;71:1098 -109.
47. Oh WK, Tay MH, Huang J. Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer? Cancer 2007;109:477-86.
48. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20.
49. Tannock IF, deWit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
50. Latif T, Wood L, Connell C, et al. Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC). Invest New Drugs 2005;23:79-84.
51. Sternberg CN, Whelan P, Hetherington J, et al. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 2005;68:2-9.
52. Petrylak D, Sartor O, Witjes F, et al. A phase III, randomized, double-blind trial of satraplatin and prednisone vs placebo and prednisone for patients with hormone refractory prostate cancer (HRPC). Prostate Cancer Symposium 2007. Abstract 145.
53. Sternberg CN, Petrylak D, Witjes F, et al. Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: Results of a randomized phase III trial. Proc Am Soc Clin Oncol 2007;25:abstract 5019.
54. Available from: http://www.prostate-cancer.org/advocacy/ SatraplatinFDA_Review.html. Accessed Jan 7, 2008.
55. Fokkema E, Groen HJ, Bauer J, Uges DR, Weil C, Smith IE. Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer. J Clin Oncol 1999;17:3822-7.
56. Judson I, Cerny T, Epelbaum R, et al. Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: an EORTC early clinical studies group investigation. Ann Oncol 1997;8:604-6.
57. Fokkema E, Lunenberg J, Putten JWG. Randomized phase II study of oral JM216 versus intravenous (iv) cisplatin in non-small cell lung cancer (NSCLC): preliminary results. Proc Am Soc Clin Oncol 1998. Abstract 1858.
58. A randomized phase II study of satraplatin (JM-216) or standard platinum therapy in patients with late relapses of epithelial ovarian cancer (CA 142-006). Bristol-Myers Squibb Report 1998:Assession No. 910068667.
59. Trudeau M, Stuart G, Hirte H, et al. A phase II trial of JM-216 in cervical cancer: an NCIC CTG study. Gynecol Oncol 2002;84:327-31.
60. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992;326:524-30.
61. Schild SE, Wong WW, Vora SA, et al. The long-term results of a pilot study of three times a day radiotherapy and escalating doses of daily cisplatin for locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2005;62:1432-7.
62. Keene KS, Harman EM, Knauf DG, McCarley D, Zlotecki RA. Five-year results of a phase II trial of hyperfractionated radiotherapy and concurrent daily cisplatin chemotherapy for stage III nonsmall-cell lung cancer. Am J Clin Oncol 2005;28:217-22.
63. Jefford M, Toner GC, Smith JG, Ngan SY, Rischin D, Guiney MJ. Phase II trial of continuous infusion carboplatin, 5-fluorouracil, and radiotherapy for localized cancer of the esophagus. Am J Clin Oncol 2002;25:277-82.
64. Jeremic B, Milicic B, Dagovic A, Vaskovic Z, Tadic L. Radiation therapy with or without concurrent low-dose daily chemotherapy in locally advanced, nonmetastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2004;22:3540-8.